Comparing laser treatment to brimonidine/timolol eye drops in patients with primary open angle glaucoma.

Not Applicable

Completed

• Conditions: Eye Diseases; Primary Open Angle Glaucoma

• Registration Number: ISRCTN30070325
• Lead Sponsor: niversity of Pikeville Kentucky College of Optometry

Brief Summary

2019 Preprint results in https://doi.org/10.21203/rs.2.473/v1 (added 28/09/2021) 2021 Results article in http://dx.doi.org/10.24966/OCR-8887/100075 (added 28/09/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-07-25
• Study Start: 2018-12-14
• Last Update Posted: 11 October 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

1. Uncontrolled primary open angle glaucoma
2. Open angle on gonioscopy
3. Aged 25 to 90 years
4. Currently taking a prostaglandin analog, but IOP not controlled with monotherapy

Exclusion Criteria

1. Best corrected visual acuity worse than 20/40 in the study eye (meaning 20/50 or worse)
2. Hx of angle closure or an occludable angle on gonioscopy
3. Untreated IOP less than or equal to 21 mmHg
4. Patients who have used a second IOP lowering medication in the past 2 months
5. Angle recession on gonioscopy
6. Pseudoexfoliation glaucoma
7. Pigment dispersion glaucoma
8. Prior incisional glaucoma surgery
9. Prior Microinvasive Glaucoma Surgery (MIGS, istent, Endocyclophotocoagulation)
10. Previous SLT or Argon Laser Trabeculoplasty (ALT)
11. Previous Laser Peripheral Iridotomy (LPI)
12. Previous refractive surgery
13. Inflammatory eye disease
14. Contraindication to any of the topical medicines including asthma, chronic obstruction pulmonary disease, bradycardia, or a hypersensitivity reaction.
15. A change in dosage, or addition of, a systemic medication that could effect IOP during the study
16. Women who are pregnant or who intend to become pregnant in the next 4 months (as verbally asked during the medical history and consenting process, no formal pregnancy test will be administered for this study)
17. Patients with significant dementia who are not able to fully comprehend the informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intraocular pressure (IOP) at baseline and 8 weeks measured using Goldman tonometry. Baseline IOP was the average of two IOP measurements taken 30 minutes apart during the baseline exam. If the IOP measurements were greater than +/- 2 mmHg, a third IOP measurement was taken 30 minutes later. All follow up exams were within +/- 2 hour from the initial baseline exam to best control for diurnal fluctuations. Additionally, at each IOP measurement, two IOP readings will be taken and averaged.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Ocular abnormality or inflammation identified using slit lamp examination of the cornea, anterior chamber, and lens at baseline and 8 weeks after the procedure.<br> 2. Visual acuity assessed using a standard Snellen chart at baseline and 8 weeks<br>